Change in HbA1c as a measure of quality of diabetes care [11]

Diabetes Care

Volumn 29, Issue 5, 2006, Pages 1183-1184

  Spitz, Adam F ^a   Kanani, Harshil ^a  

^a Presbyterian Endocrinology and Osteoporosis Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN;

DIABETES MELLITUS; DISEASE MARKER; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; LETTER; MEDICAL PRACTICE; MEDICAL SOCIETY; METHODOLOGY; MICROANGIOPATHY; PATIENT REFERRAL; RETINOPATHY; SCORING SYSTEM; BLOOD; HOSPITALIZATION;

BIOLOGICAL MARKERS; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; QUALITY INDICATORS, HEALTH CARE; SEVERITY OF ILLNESS INDEX;

EID: 85047698296     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc05-2032     Document Type: Letter

References (5)

1. Diabetes Physician Recognition Program [article online], 1997. Available from www.NCQA.org/dprp/
2. Smith JJ: NCQA/HEDIS guidelines for diabetes. Manag Care 10 (Suppl. 2):3-5, 2001
3. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 28:S4-S36, 2005
4. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 24:S33-S43, 2001
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 329:977-986, 1993